Ratings by Jones Trading (Boris Peaker)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/29/2026 | Enliven Therapeutics | ELVN | Maintain | Buy (N/A) |
|
Details | ||
| 6/15/2026 | Elicio Therapeutics | ELTX | Downgrade | Hold (Buy) |
14.85 (3.11) |
-79.06% | Details | |
| 5/14/2026 | Adlai Nortye Ltd. | ANL | New Coverage | Buy (N/A) |
13.94 (11.53) |
-17.29% | Details | |
| 5/6/2026 | OnKure Therapeutics Inc. | OKUR | Downgrade | Hold (Buy) |
4.52 (4.20) |
-7.08% | Details | |
| 4/28/2026 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Whitehawk Therapeutics | WHWK | New Coverage | Buy (N/A) |
3.51 (3.89) |
10.83% | Details | |
| 4/6/2026 | Protara Therapeutics | TARA | New Coverage | Buy (N/A) |
5.11 (4.10) |
-19.77% | Details | |
| 4/6/2026 | Prime Medicine | PRME | New Coverage | Buy (N/A) |
3.32 (3.13) |
-5.72% | Details | |
| 4/6/2026 | ORIC Pharmaceuticals | ORIC | New Coverage | Buy (N/A) |
8.89 (10.73) |
20.7% | Details | |
| 4/6/2026 | OnKure Therapeutics Inc. | OKUR | New Coverage | Buy (N/A) |
4.29 (4.52) |
5.36% | Details | |
| 4/6/2026 | Oncolytics Biotech | ONCY | New Coverage | Hold (N/A) |
0.96 (0.85) |
-11.46% | Details | |
| 4/6/2026 | Nuvation Bio Inc | NUVB | New Coverage | Buy (N/A) |
4.41 (5.80) |
31.52% | Details | |
| 4/6/2026 | Monopar Therapeutics | MNPR | New Coverage | Buy (N/A) |
55.13 (111.12) |
101.56% | Details | |
| 4/6/2026 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
14.84 (16.26) |
9.57% | Details | |
| 4/6/2026 | IN8bio Inc. | INAB | New Coverage | Buy (N/A) |
1.44 (1.33) |
-7.64% | Details | |
| 4/6/2026 | Enliven Therapeutics | ELVN | New Coverage | Buy (N/A) |
38.83 (53.20) |
37.01% | Details | |
| 4/6/2026 | Elicio Therapeutics | ELTX | New Coverage | Buy (N/A) |
10.65 (14.85) |
39.44% | Details | |
| 4/6/2026 | Editas Medicine | EDIT | New Coverage | Buy (N/A) |
2.67 (2.98) |
11.61% | Details | |
| 4/6/2026 | Day One Biopharmaceuticals | DAWN | New Coverage | Hold (N/A) |
21.45 (21.53) |
0.37% | Details | |
| 4/6/2026 | Curis | CRIS | New Coverage | Buy (N/A) |
0.55 (4.63) |
741.82% | Details | |
| 4/6/2026 | Cullinan Oncology Inc. | CGEM | New Coverage | Buy (N/A) |
14.43 (17.69) |
22.59% | Details | |
| 4/6/2026 | Context Therapeutics | CNTX | New Coverage | Buy (N/A) |
2.72 (0.60) |
-77.94% | Details | |
| 4/6/2026 | CG Oncology | CGON | New Coverage | Buy (N/A) |
67.48 (71.85) |
6.48% | Details | |
| 4/6/2026 | CervoMed | CRVO | New Coverage | Buy (N/A) |
4.14 (3.08) |
-25.6% | Details | |
| 4/6/2026 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Hold (N/A) |
4.29 (4.42) |
3.03% | Details | |
| 4/6/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Buy (N/A) |
21.47 (27.76) |
29.3% | Details | |
| 4/6/2026 | Beam Therapeutics Inc | BEAM | New Coverage | Buy (N/A) |
24.66 (27.53) |
11.64% | Details | |
| 4/6/2026 | aTyr Pharma | ATYR | New Coverage | Hold (N/A) |
0.85 (0.51) |
-40% | Details | |
| 4/6/2026 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
24.89 (33.19) |
33.35% | Details | |
| 4/6/2026 | Adicet Bio Inc. | ACET | New Coverage | Buy (N/A) |
6.99 (8.12) |
16.17% | Details |
